A study showed that activated TLR8 could prevent cAMP production in tumor cells and block the tumor-induced conversion of naive and tumor-specific T cells into senescent cells, therefore enhancing antitumor immunity in vivo [136]. This evidence concerns the gene TLR8 and neoplasm.